Viracta Therapeutics (FRA:RYI) Pre-Tax Income : €-44.36 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Viracta Therapeutics Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Viracta Therapeutics's pretax income for the three months ended in Mar. 2024 was €-8.41 Mil. Its pretax income for the trailing twelve months (TTM) ended in Mar. 2024 was €-44.36 Mil. Viracta Therapeutics's pretax margin was %.

Viracta Therapeutics Pre-Tax Income Historical Data

The historical data trend for Viracta Therapeutics's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viracta Therapeutics Pre-Tax Income Chart

Viracta Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Pre-Tax Income

-15.63

-101.56

-46.44

-46.82

Viracta Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Pre-Tax Income	Get a 7-Day Free Trial												-11.40	-11.52	-11.81	-12.62	-8.41

Competitive Comparison of Viracta Therapeutics's Pre-Tax Income

For the Biotechnology subindustry, Viracta Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viracta Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viracta Therapeutics's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Viracta Therapeutics's Pre-Tax Income falls into.

Viracta Therapeutics Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Viracta Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-46.485	+	-0.006	+	-3.397	+	3.067	+	0.00099999999999767
	=	-46.82

Viracta Therapeutics's Pretax Income for the quarter that ended in Mar. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-12.766	+	4.601	+	-0.789	+	0.545	+	-0.00099999999999945
	=	-8.41

Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-44.36 Mil.

Viracta Therapeutics (FRA:RYI) Pre-Tax Income Explanation

Viracta Therapeutics's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-8.41	/	0
	=	%

Viracta Therapeutics Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Viracta Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Viracta Therapeutics (FRA:RYI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viracta Therapeutics Inc (FRA:RYI) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

VIRX:USA RYIS:Germany

Address

2533 South Coast Highway 101, Suite 210, Cardiff, CA, USA, 92007

Website

https://www.viracta.com

Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. Its lead product candidate is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people who have received organ transplants.